The data analysis used the recently introduced SeqSolve Next Generation Sequencing (NGS) functional bioinformatics analysis software and Direct RNA Sequencing. The discovered novel polyadenylation genomic sites and signals will provide a unique reference resource for the scientific community.
The published results demonstrate the crucial importance of appropriate bioinformatics software in maximizing the value of the data produced by high-end last generation high-throughput sequencing instruments. This is important in a market environment, where the cost of sequencing is plummeting, but the revolution is limited by a bottleneck at the level of downstream functional data analysis and interpretation.
The SeqSolve analysis software is an independent, multi-organism sequencing solution, performing tertiary level analyzes for biologically relevant results. It features the exclusive Click and GO(R) technology for seamless transcriptome profiling automation and quality control, besides the TIBCO Spotfire(R) platform for scientific data visualization and extended downstream analysis.
“The article in Cell follows an article published in Nature in July 2010 about the initial SeqSolve analysis and demonstrates both our commitment to and the value of our SeqSolve software,” said Dr. Michael J. McManus, CEO, Integromics. “Integromics developed the software to perform high-throughput sequencing data analysis and to discover previously unidentified mechanisms, events, signals and correlations in the genomes of human and other organisms.”
The Cell article, entitled ‘Comprehensive Polyadenylation Site Maps in Yeast and Human Reveal Pervasive Alternative Polyadenylation’ (Vol. 143, Issue 6, p. 1018, http://www.cell.com/abstract/S0092-8674%2810%2901300-0), was co-authored by Dr. Sylvain Foissac from Integromics, SL.; Drs. Bino John, A. Paula Monaghan, Elane Fishilevich and Sang Woo Kim, from the University of Pittsburgh School of Medicine; and Drs. Fatih Ozsolak, Philipp Kapranov and Patrice Milos from Helicos BioSciences Corporation.